Megan C Gallagher1, Sarah Haessler1, Elizabeth Pecoy-Whitcomb2, Jonathan Bayuk3. 1. From the Division of Infectious Diseases, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts. 2. Employee Health Services, Baystate Health, Springfield, Massachusetts; and. 3. Division of Allergy and Immunology, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts.
Abstract
Background: After Emergency Use Authorization of the coronavirus disease 2019 (COVID-19) vaccines, guidance was provided by the Centers for Disease Control and Prevention that persons with an immediate allergic reaction to a messenger RNA (mRNA) COVID-19 vaccine should be evaluated by an allergist/immunologist before receipt of the second dose. Methods: In vaccinating health-care personnel, we referred those with significant reactions to allergy/immunology specialists so that they could safely receive the second dose. Results: We found that many reactions after the first dose were nonallergic but could be debilitating and a barrier to the second dose. We created a protocol of premedications to allow health-care personnel to safely receive their second mRNA COVID-19 vaccine dose. Conclusion: This protocol is adaptable and can be used in settings where allergy/immunology referral is not immediately available.
Background: After Emergency Use Authorization of the coronavirus disease 2019 (COVID-19) vaccines, guidance was provided by the Centers for Disease Control and Prevention that persons with an immediate allergic reaction to a messenger RNA (mRNA) COVID-19 vaccine should be evaluated by an allergist/immunologist before receipt of the second dose. Methods: In vaccinating health-care personnel, we referred those with significant reactions to allergy/immunology specialists so that they could safely receive the second dose. Results: We found that many reactions after the first dose were nonallergic but could be debilitating and a barrier to the second dose. We created a protocol of premedications to allow health-care personnel to safely receive their second mRNA COVID-19 vaccine dose. Conclusion: This protocol is adaptable and can be used in settings where allergy/immunology referral is not immediately available.
Authors: Aleena Banerji; Paige G Wickner; Rebecca Saff; Cosby A Stone; Lacey B Robinson; Aidan A Long; Anna R Wolfson; Paul Williams; David A Khan; Elizabeth Phillips; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2020-12-31
Authors: Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Eileen Gallagher; Ruth Simmons; Simon Thelwall; Julia Stowe; Elise Tessier; Natalie Groves; Gavin Dabrera; Richard Myers; Colin N J Campbell; Gayatri Amirthalingam; Matt Edmunds; Maria Zambon; Kevin E Brown; Susan Hopkins; Meera Chand; Mary Ramsay Journal: N Engl J Med Date: 2021-07-21 Impact factor: 91.245